Sun Pharma Advanced Research Company Limited

rs,

from time to time by or on behalf of the Company. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward looking sta

rs 0

ion Atopic Dermatitis 0 Provides an alternate mechanism to IL-4/IL-13 antibodies and JAK inhibitors 0 Studies being expanded to Europe and Canada SCD-153 Topical application may potentially provide a

4%

; expected to grow above 14 mn by 2040 sparc0 0 PD population outgrowing overall population (2-4% growth in PD vs. 1% global population growth) 0 DMTs can make significant impact to the lives of

1%

bove 14 mn by 2040 sparc0 0 PD population outgrowing overall population (2-4% growth in PD vs. 1% global population growth) 0 DMTs can make significant impact to the lives of PD patients by chan

87%

rim analysis expected to be available by March 2024 Part 2 0 Study initiated in Q4 2021 0 ~87% of eligible patients enrolled in Part 2 0 Continuing treatment for additional 9 months 0 Cont

40%

t cardiac events reported in the patients recruited sparc Number of patients randomized 0 Over 40% patients enrolled from the US 250 200 150 100 50 0 216 0 Grade 3/4 events reported in 6.1

6.1%

40% patients enrolled from the US 250 200 150 100 50 0 216 0 Grade 3/4 events reported in 6.1% patients 89 85 76 0 GI and rash were the most common AEs reported No changes in study protoc

50%

lopecia Areata1 0 Estimated 6.7 mn people in the US and 160 mn people worldwide have AA2 0 ~ 50% can experience spontaneous hair regrowth within one year, the majority often relapse 0 Current

rs. 2017

m Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011 | CD8: Cluster of Differentiation 8 SPARC © 2023 36 • SCD-153 has demonstrated promisi

3%

r G r i a H ) p u o r g / 8 - 7 = n , D S ± n a e M ( 0 0 Vehicle, Thrice-a-week SCD-153, 3%, Thrice-a-week ...... * * * * * 4 8 12 16 Time (Weeks) Vehicle thrice -a- week SCD-153

100%

* * * 4 8 12 16 Time (Weeks) Vehicle thrice -a- week SCD-153 at 3% thrice-a- week n=7; 85–100% alopecia; >45 weeks age Spontaneous severe C3H/HeJ AA mouse model Data are represented as mean ± S

24.19%

ach ~ 25 bn by 2038 sparc0 FDA 12 FDA Approved ADCs US$ 25.34 Bn Projected ADC market by 2028 24.19% CAGR from 2023 to 2028 Approved ADCs 2017 2020 2022 2019 2021 t 0 Besponsa® 0 Polivy®

“Apoptosis of target cell Payload Microtubule disruption Endosome 3.”

“To evaluate the plasma pharmacokinetics of SCD-153 and its metabolite DCGI: Drug Controller General of India | IMP: Investigational Medicinal Product SPARC © 2023 39 SCD-153: potential to expand in other epidermal diseases 0 sparc Trigger Melanocyte-containing skin cell (target cell) Disease-causing immune cell IFNγ IFNγ receptor CXCR3 -----+ ~ ---+------, 0 0 ~ JAK1/2 0 ~ 0 C=:> CXCL9 CXCL10 STAT1 - CD8+ T cell c=) Skin cell 0 0 0 IFNγ induces CXCL9, CXCL10 & CXCL11 in vitiligous skin.”

Sleep Disorders

1

Autonomic dysfuction

1

Primary Objective

1

Secondary Objective

1

Sleep Disorders

REM sleep behaviour disorder Daytime somnolence Restless legs syndrome Periodic limb movement in sleep Depression Cognitive impairment EARLY STAGES ADVANCED STAGES PROSEEK target population Vodobatinib future development Dyskinesia On-Off Tremor Rigidity Bradykinesia Pain in medial collateral ligament Dysphagia Urinary symptoms Orthostatic hypotension Dementia Psychosis Hallucinations OCD Postural changes Dysphagia Gait's apraxia Freezing Falls Dystonia Treatment Complications Motor symptoms Non-motor symptoms Gastrointestinal symptoms and constipation

Autonomic dysfuction

Orthostatic hypotension Urogenital dysfunction i n o s s e r g o r p e s a e s D i -20 -10 0 10 20 Time from diagnosis (years) Vodobatinib can emerge as the protective backbone across the continuum of care for synucleopathies and other neurodegenerative disorders resulting from misfolded proteins Chart adapted from Is insulin-like growth factor-1 involved in Parkinson’s disease development? Castilla-Cortázar et al. J Transl Med (2020) 18:70 MSA: Multiple System Atrophy | DLB: Dementia with Lewy Bodies | OCD: Obsessive Compulsive Disorder SPARC © 2023 8 Vibozilimod* Optionality beyond PROSEEK 0 sparc SPARC pipeline includes multiple high value assets with platform potential 0 SPARC’s immunology program will provide additional efficacy and safety data points in 2024 0 Oncology offers a potential hedge and anchor for future portfolio build across modalities 0 Additional bets to understand underlying mechanisms in neurodegenerative diseases - UK DRI collaboration Immunology Oncology Led by

Primary Objective

0 To evaluate the safety and local tolerability [_X_X_X_X_J 0 In-house assessments until 48 hours Safety follow up Day10 IMP Application Day 1 Site visit at 72 hours Check in Day -1

Secondary Objective

To evaluate the plasma pharmacokinetics of SCD-153 and its metabolite DCGI: Drug Controller General of India | IMP: Investigational Medicinal Product SPARC © 2023 39 SCD-153: potential to expand in other epidermal diseases 0 sparc Trigger Melanocyte-containing skin cell (target cell) Disease-causing immune cell IFNγ IFNγ receptor CXCR3 -----+ ~ ---+------, 0 0 ~ JAK1/2 0 ~ 0 C=:> CXCL9 CXCL10 STAT1 - CD8+ T cell c=) Skin cell 0 0 0 IFNγ induces CXCL9, CXCL10 & CXCL11 in vitiligous skin. These chemokines recruit pathogenic CD8+ T cells to the pigment-containing melanocyte in the epidermis CD8+ T cells release cytokines that destroy the melanocytes causing depigmentation studies have shown that SCD-153 inhibits: In-vitro 0 Expression of CXCL9, 10 and 11 in stimulated human keratinocytes 0 IFNγ secretion from stimulated murine CD8+ T cells Image adapted from Picarodo et al. Nat. Rev. Dis. Primers (2015) CXCL: Chemokine (C-X-C motif) ligand | CXCR3: Chemokine (C-X-C motif) receptor 3 SPARC